212 related articles for article (PubMed ID: 22773834)
1. Chemoenzymatic synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities.
Xu Y; Pempe EH; Liu J
J Biol Chem; 2012 Aug; 287(34):29054-61. PubMed ID: 22773834
[TBL] [Abstract][Full Text] [Related]
2. Low anticoagulant heparin oligosaccharides as inhibitors of BACE-1, the Alzheimer's β-secretase.
Zhang X; Zhao X; Lang Y; Li Q; Liu X; Cai C; Hao J; Li G; Yu G
Carbohydr Polym; 2016 Oct; 151():51-59. PubMed ID: 27474542
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of 3-
Li J; Su G; Xu Y; Arnold K; Pagadala V; Wang C; Liu J
ACS Chem Biol; 2021 Oct; 16(10):2026-2035. PubMed ID: 34351732
[TBL] [Abstract][Full Text] [Related]
4. Fucosylated chondroitin sulfate oligosaccharides exert anticoagulant activity by targeting at intrinsic tenase complex with low FXII activation: Importance of sulfation pattern and molecular size.
Li J; Li S; Yan L; Ding T; Linhardt RJ; Yu Y; Liu X; Liu D; Ye X; Chen S
Eur J Med Chem; 2017 Oct; 139():191-200. PubMed ID: 28800457
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.
Lane DA; Denton J; Flynn AM; Thunberg L; Lindahl U
Biochem J; 1984 Mar; 218(3):725-32. PubMed ID: 6721831
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.
Walenga JM; Jeske WP; Bara L; Samama MM; Fareed J
Thromb Res; 1997 Apr; 86(1):1-36. PubMed ID: 9172284
[No Abstract] [Full Text] [Related]
7. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
8. The establishment and validation of efficient assays for anti-IIa and anti-Xa activities of heparin sodium and heparin calcium.
Suzuki T; Ishii-Watabe A; Hashii N; Nakagawa Y; Takahashi T; Ebisawa A; Nishi S; Fujita N; Bando A; Sekimoto Y; Miyata K; Endo T; Otsu T; Sugimoto S; Kondou T; Fujita Y; Miyanaga N; Mashimo M; Shimada N; Yoden H; Shimamura H; Kurata Y; Koyama S; Kawasaki N
Biologicals; 2013 Nov; 41(6):415-23. PubMed ID: 24095600
[TBL] [Abstract][Full Text] [Related]
9. [From heparin to synthetic antithrombotic oligosaccharides].
Petitou M
Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
[TBL] [Abstract][Full Text] [Related]
10. Rational design of anticoagulant drugs using oligosaccharide chemistry.
El Hadri A; Petitou M
Chimia (Aarau); 2011; 65(1-2):14-7. PubMed ID: 21469438
[TBL] [Abstract][Full Text] [Related]
11. Design of biologically active heparan sulfate and heparin using an enzyme-based approach.
Peterson S; Frick A; Liu J
Nat Prod Rep; 2009 May; 26(5):610-27. PubMed ID: 19387498
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of thrombin-inhibiting heparin mimetics without side effects.
Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
Nature; 1999 Apr; 398(6726):417-22. PubMed ID: 10201371
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of new synthetic heparin mimetics.
Hérault JP; Bernat A; Roye F; Michaux C; Schaeffer P; Bono F; Petitou M; Herbert JM
Thromb Haemost; 2002 Jun; 87(6):985-9. PubMed ID: 12083506
[TBL] [Abstract][Full Text] [Related]
14. The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma.
Bendetowicz AV; Bara L; Samama MM
Thromb Res; 1990 Jun; 58(5):445-54. PubMed ID: 2164262
[TBL] [Abstract][Full Text] [Related]
15. The C-terminal fragment of axon guidance molecule Slit3 binds heparin and neutralizes heparin's anticoagulant activity.
Condac E; Strachan H; Gutierrez-Sanchez G; Brainard B; Giese C; Heiss C; Johnson D; Azadi P; Bergmann C; Orlando R; Esmon CT; Harenberg J; Moremen K; Wang L
Glycobiology; 2012 Sep; 22(9):1183-92. PubMed ID: 22641771
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans.
Kaiser B; Hoppensteadt DA; Jeske W; Wun TC; Fareed J
Thromb Res; 1994 Sep; 75(6):609-16. PubMed ID: 7831680
[TBL] [Abstract][Full Text] [Related]
17. Directing the biological activities of heparan sulfate oligosaccharides using a chemoenzymatic approach.
Xu Y; Wang Z; Liu R; Bridges AS; Huang X; Liu J
Glycobiology; 2012 Jan; 22(1):96-106. PubMed ID: 21835782
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
Walenga JM; Petitou M; Lormeau JC; Samama M; Fareed J; Choay J
Thromb Res; 1987 Apr; 46(2):187-98. PubMed ID: 3603420
[TBL] [Abstract][Full Text] [Related]
19. Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases.
Patey SJ; Edwards EA; Yates EA; Turnbull JE
J Med Chem; 2006 Oct; 49(20):6129-32. PubMed ID: 17004727
[TBL] [Abstract][Full Text] [Related]
20. Preparation of heparin/heparan sulfate oligosaccharides with internal N-unsubstituted glucosamine residues for functional studies.
Wei Z; Deakin JA; Blaum BS; Uhrín D; Gallagher JT; Lyon M
Glycoconj J; 2011 Dec; 28(8-9):525-35. PubMed ID: 21948150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
